Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amneal Expands in Ireland | Contract Pharma

What are you searching for?

Sign in
Breaking News

Amneal Expands in Ireland

U.S. generics manufacturer acquires Tipperary plant to spur European expansion

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amneal Pharmaceuticals LLC, a U.S.-based generic drug manufacturer, has purchased a 200,000 square foot facility in Cashel, County Tipperary, Ireland.

The former Johnson & Johnson plant was sold by owner Solidus Private Equity, a Singapore-based investment firm. Amneal worked closely with Foreign Direct Investment agency IDA Ireland.

The investment is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.

The Cashel site will be dedicated to R&D and production of metered dose and dry powder inhalers (MDIs and DPIs) as well as biosimilars—all high-end specialty medications—with each product occupying approximately 50% of the building. Amneal expects to hire an estimated 250-300 employees at full build-out.

“Our new Ireland facility is critical to Amneal’s long-term global growth, in Europe, the U.S. and throughout the world,” said Chintu Patel, Amneal co-chief executive officer and co-chairman. “We appreciate the outstanding support from IDA Ireland and others in helping us establish ourselves in County Tipperary and are excited to launch our operations here.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics